Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review ; volume:42 ; number:03 ; year:2021 ; pages:240-246
Indian journal of medical & paediatric oncology ; 42, Heft 03 (2021), 240-246
- Contributor
-
Dabkara, Deepak
- DOI
-
10.1055/s-0041-1732851
- URN
-
urn:nbn:de:101:1-2021110411145750163281
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.09.2027, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dabkara, Deepak
Other Objects (12)
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Prostate cancer
Prostate cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Prostate cancer
Prostate cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer
Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Prostate cancer